Table Info

Table 5.

Summary of preclinical investigations in PRIT of NHL

Radionucleotide	Lymphoma	Targeting antibody	Comparison with conventional RIT	Reference
⁹⁰Y-DOTA-biotin	Burkitt lymphoma (Ramos)	Anti-CD20 1F5-SA	Yes	[62, 63]
		Anti-CD20 1F5-SA	No	[64]
		Anti-CD20 2H7-Fc-C825 bsMAb	No	[69]
	Burkitt lymphoma (Ramos and Raji), transformed FL (FL-18)	Anti-CD20 1F5-SA, anti-CD22 HD39, anti-HLA-DR Lym-1	Yes	[65]
	Burkitt lymphoma (Namalwa)	Anti-CD38 028-Fc-C825 bsMAb	No	[70]
	Mantle cell lymphoma (Granta-519)	Anti-CD20 1F-5SA	No	[64]
¹⁷⁷Lu-DOTA-biotin	Burkitt lymphoma (Ramos)	Anti-CD20 1F-5SA	No	[64]
¹⁷⁷Lu-DOTA-biotin	Mantle cell lymphoma (Granta-519)	Anti-CD20 1F-5SA	No	[64]
²¹³Bi-DOTA-biotin	Burkitt lymphoma (Ramos)	Anti-CD20 1F5(scFv)₄ SA	Yes	[66]
⁹⁰Y-DOTA-histamine-succinyl-glycine (HSG)	Burkitt lymphoma (Ramos)	Anti-CD20 IMMU-106 bispecific mAb (bsMAb)	Yes	[71]
⁹⁰Y-DOTA-histamine-succinyl-glycine (HSG)	Burkitt lymphoma (Ramos)	Anti-CD20 TF4, trivalent-Fab bsMAb	Yes	[72]

Declarations

Acknowledgments

We thank Kumiko Fukushima for secretarial assistance (Kumamoto University).

Author contributions

HG: Conceptualization, Writing—original draft, Writing—review & editing, Supervision. SO: Conceptualization, Writing—review & editing, Supervision. YS: Writing—review & editing. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med. 2008;359:613–26. [DOI] [PubMed]

Goto H, Kojima Y, Matsuda K, Kariya R, Taura M, Kuwahara K, et al. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma. Eur J Cancer. 2014;50:1836–46. [DOI] [PubMed]

Goto H, Kudo E, Kariya R, Taura M, Katano H, Okada S. Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. J Cancer Res Clin Oncol. 2015;141:465–74. [DOI] [PubMed]

Montoto S, Davies AJ, Matthews J, Calaminici M, Norton AJ, Amess J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426–33. [DOI] [PubMed]

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23:4117–26. [DOI] [PubMed]

Farooq U, Maurer MJ, Thompson CA, Thanarajasingam G, Inwards DJ, Micallef I, et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol. 2017;179:50–60. [DOI] [PubMed] [PMC]

Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med. 1988;29:226–34. [PubMed]

Nourigat C, Badger CC, Bernstein ID. Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst. 1990;82:47–50. [DOI] [PubMed]

Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004;10:7792–8. [DOI] [PubMed]

10.

Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20⁺ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429–31. [DOI] [PubMed]

11.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–63. [DOI] [PubMed]

12.

Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–9. [DOI] [PubMed]

13.

Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54–8. [DOI]

14.

Cicone F, Russo E, Carpaneto A, Prior JO, Delaloye AB, Scopinaro F, et al. Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after ⁹⁰Y-ibritumomab-tiuxetan. Hematol Oncol. 2011;29:131–8. [DOI] [PubMed]

15.

Scholz CW, Pinto A, Linkesch W, Linden O, Viardot A, Keller U, et al. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol. 2013;31:308–13. [DOI] [PubMed]

16.

Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, et al. Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. J Clin Oncol. 2014;32:212–8. [DOI] [PubMed]

17.

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156–64. [DOI] [PubMed]

18.

Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, et al. ⁹⁰Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-line indolent trial. J Clin Oncol. 2013;31:1977–83. [DOI] [PubMed]

19.

Karmali R, Larson ML, Shammo JM, Gregory SA, O’Brien T, Venugopal P. Phase 2 study of CHOP-R-14 followed by ⁹⁰Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma. Mol Clin Oncol. 2017;6:627–33. [DOI] [PubMed] [PMC]

20.

Krishnan A, Palmer JM, Tsai NC, Simpson JR, Nademanee A, Raubitschek A, et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol Blood Marrow Transplant. 2012;18:441–50. [DOI] [PubMed] [PMC]

21.

Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol. 2005;23:7565–73. [DOI] [PubMed]

22.

Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. ¹³¹I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–9. [DOI] [PubMed]

23.

Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, et al. Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus ¹³¹I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016. J Clin Oncol. 2018;36:697–703. [DOI] [PubMed] [PMC]

24.

Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood. 2003;102:2351–7. [DOI] [PubMed]

25.

Morschhauser F, Kraeber-Bodere F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin’s lymphoma. J Clin Oncol. 2010;28:3709–16. [DOI] [PubMed]

26.

Blakkisrud J, Londalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, et al. Tumor-absorbed dose for non-Hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate ¹⁷⁷Lu-lilotomab satetraxetan. J Nucl Med. 2017;58:48–54. [DOI] [PubMed]

27.

Blakkisrud J, Londalen A, Dahle J, Turner S, Holte H, Kolstad A, et al. Red marrow-absorbed dose for non-Hodgkin lymphoma patients treated with ¹⁷⁷Lu-lilotomab satetraxetan, a novel anti-CD37 antibody-radionuclide conjugate. J Nucl Med. 2017;58:55–61. [DOI] [PubMed]

28.

Blakkisrud J, Holtedahl JE, Londalen A, Dahle J, Bach-Gansmo T, Holte H, et al. Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody-radionuclide conjugate ¹⁷⁷Lu-lilotomab satetraxetan. J Nucl Med. 2018;59:704–10. [DOI] [PubMed]

29.

Stokke C, Blakkisrud J, Londalen A, Dahle J, Martinsen ACT, Holte H, et al. Pre-dosing with lilotomab prior to therapy with ¹⁷⁷Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. Eur J Nucl Med Mol Imaging. 2018;45:1233–41. [DOI] [PubMed] [PMC]

30.

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, et al. Phase 1/2a study of ¹⁷⁷Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4:4091–101. [DOI] [PubMed] [PMC]

31.

Dahle J, Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, et al. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin’s lymphoma. Anticancer Res. 2013;33:85–95. [PubMed]

32.

Repetto-Llamazares AH, Larsen RH, Patzke S, Fleten KG, Didierlaurent D, Pichard A, et al. Targeted cancer therapy with a novel anti-CD37 beta-particle emitting radioimmunoconjugate for treatment of non-hodgkin lymphoma. PLoS One. 2015;10:e0128816. [DOI] [PubMed] [PMC]

33.

Repetto-Llamazares AHV, Malenge MM, O’Shea A, Eiriksdottir B, Stokke T, Larsen RH, et al. Combination of ¹⁷⁷Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin’s lymphoma. Eur J Haematol. 2018;101:522–31. [DOI] [PubMed]

34.

Maaland AF, Heyerdahl H, O’Shea A, Eiriksdottir B, Pascal V, Andersen JT, et al. Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate ¹⁷⁷Lu-NNV003. Eur J Nucl Med Mol Imaging. 2019;46:2311–21. [DOI] [PubMed] [PMC]

35.

Shim K, Longtine MS, Abou DS, Hoegger MJ, Laforest RS, Thorek DLJ, et al. Cure of disseminated human lymphoma with [¹⁷⁷Lu]Lu-ofatumumab in a preclinical model. J Nucl Med. 2023;64:542–8. [DOI] [PubMed] [PMC]

36.

Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012;18:1039–50. [DOI] [PubMed] [PMC]

37.

Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5:611–5. [PubMed]

38.

Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood. 2009;113:4885–93. [DOI] [PubMed]

39.

Gopal AK, Press OW, Wilbur SM, Maloney DG, Pagel JM. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood. 2008;112:830–5. [DOI] [PubMed] [PMC]

40.

Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA, McBride WJ, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med. 2009;50:444–53. [DOI] [PubMed]

41.

Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of ⁹⁰Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res. 2008;14:6154–60. [DOI] [PubMed]

42.

Weber T, Botticher B, Mier W, Sauter M, Kramer S, Leotta K, et al. High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a ¹⁷⁷Lu-based CD22-specific radioimmunoconjugate and rituximab. Eur J Nucl Med Mol Imaging. 2016;43:489–98. [DOI] [PubMed]

43.

Witzig TE, Tomblyn MB, Misleh JG, Kio EA, Sharkey RM, Wegener WA, et al. Anti-CD22 ⁹⁰Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 2014;99:1738–45. [DOI] [PubMed] [PMC]

44.

Dahle J, Borrebaek J, Jonasdottir TJ, Hjelmerud AK, Melhus KB, Bruland OS, et al. Targeted cancer therapy with a novel low-dose rate α-emitting radioimmunoconjugate. Blood. 2007;110:2049–56. [DOI] [PubMed]

45.

Durand-Panteix S, Monteil J, Sage M, Garot A, Clavel M, Saidi A, et al. Preclinical study of ²¹²Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma. Br J Cancer. 2021;125:1657–65. [DOI] [PubMed] [PMC]

46.

Maaland AF, Saidi A, Torgue J, Heyerdahl H, Stallons TAR, Kolstad A, et al. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate ²¹²Pb-NNV003. PLoS One. 2020;15:e0230526. [DOI] [PubMed] [PMC]

47.

Havlena GT, Kapadia NS, Huang P, Song H, Engles J, Brechbiel M, et al. Cure of micrometastatic B-cell lymphoma in a SCID mouse model using ²¹³Bi-anti-CD20 monoclonal antibody. J Nucl Med. 2023;64:109–16. [DOI] [PubMed] [PMC]

48.

Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, et al. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood. 2015;125:2111–9. [DOI] [PubMed] [PMC]

49.

Longtine MS, Shim K, Hoegger MJ, Benabdallah N, Abou DS, Thorek DLJ, et al. Cure of disseminated human lymphoma with [²²⁵Ac]Ac-ofatumumab in a preclinical model. J Nucl Med. 2023;64:924–31. [DOI] [PubMed] [PMC]

50.

Linden O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A, et al. ²²⁷Th-labeled anti-CD22 antibody (BAY 1862864) in relapsed/refractory CD22-positive non-Hodgkin lymphoma: a first-in-human, phase I study. Cancer Biother Radiopharm. 2021;36:672–81. [DOI] [PubMed]

51.

Gorin JB, Menager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, et al. Antitumor immunity induced after α irradiation^1,2,3. Neoplasia. 2014;16:319–28. [DOI] [PubMed] [PMC]

52.

Liu T, Pei P, Shen W, Hu L, Yang K. Radiation-induced immunogenic cell death for cancer radioimmunotherapy. Small Methods. 2023;7:2201401. [DOI] [PubMed]

53.

Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with ²²⁵Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802. [DOI] [PubMed]

54.

Sathekge M, Bruchertseifer F, Knoesen O, Reyneke F, Lawal I, Lengana T, et al. ²²⁵Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2019;46:129–38. Erratum in: Eur J Nucl Med Mol Imaging. 2019;46:1988. [DOI] [PubMed] [PMC]

55.

Turkington TG, Zalutsky MR, Jaszczak RJ, Garg PK, Vaidyanathan G, Coleman RE. Measuring astatine-211 distributions with SPECT. Phys Med Biol. 1993;38:1121. [DOI] [PubMed]

56.

Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody-drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18:3–19. [DOI] [PubMed]

57.

Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of resistance to antibody-drug conjugates. Cancers (Basel). 2023;15:1278. [DOI] [PubMed] [PMC]

58.

Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, et al. Naturally occurring antibodies devoid of light chains. Nature. 1993;363:446–8. [DOI] [PubMed]

59.

Krasniqi A, D’Huyvetter M, Xavier C, Van der Jeught K, Muyldermans S, Van Der Heyden J, et al. Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma. Mol Cancer Ther. 2017;16:2828–39. [DOI] [PubMed]

60.

Mehrpouri M. The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: a possible therapeutic target in hematologic malignancies. Eur J Pharmacol. 2022;920:174831. [DOI] [PubMed]

61.

Lapa C, Hanscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA, et al. Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma. J Nucl Med. 2019;60:60–4. [DOI] [PubMed]

62.

Press OW, Corcoran M, Subbiah K, Hamlin DK, Wilbur DS, Johnson T, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98:2535–43. [DOI] [PubMed]

63.

Subbiah K, Hamlin DK, Pagel JM, Wilbur DS, Meyer DL, Axworthy DB, et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J Nucl Med. 2003;44:437–45. [PubMed]

64.

Frost SH, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, et al. Comparative efficacy of ¹⁷⁷Lu and ⁹⁰Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models. PLoS One. 2015;10:e0120561. [DOI] [PubMed] [PMC]

65.

Pagel JM, Orgun N, Hamlin DK, Wilbur DS, Gooley TA, Gopal AK, et al. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood. 2009;113:4903–13. [DOI] [PubMed] [PMC]

66.

Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010;116:4231–9. [DOI] [PubMed] [PMC]

67.

Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, et al. Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin’s lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000;15:15–29. [DOI] [PubMed]

68.

Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood. 2004;104:227–36. [DOI] [PubMed]

69.

Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH, et al. Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B-cell cancers. Cancer Res. 2016;76:6669–79. [DOI] [PubMed] [PMC]

70.

Green DJ, O’Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, et al. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood. 2018;131:611–20. [DOI] [PubMed] [PMC]

71.

Sharkey RM, Karacay H, Chang CH, McBride WJ, Horak ID, Goldenberg DM. Improved therapy of non-Hodgkin’s lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia. 2005;19:1064–9. [DOI] [PubMed]

72.

Sharkey RM, Karacay H, Litwin S, Rossi EA, McBride WJ, Chang CH, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin’s lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res. 2008;68:5282–90. [DOI] [PubMed] [PMC]

73.

Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res. 2005;11:7109s–21s. [DOI] [PubMed]

74.

Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009;50:1500–8. [DOI] [PubMed] [PMC]

75.

Natarajan A, Habte F, Gambhir SS. Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model. Bioconjug Chem. 2012;23:1221–9. [DOI] [PubMed] [PMC]

76.

Natarajan A, Gowrishankar G, Nielsen CH, Wang S, Iagaru A, Goris ML, et al. Positron emission tomography of ⁶⁴Cu-DOTA-Rituximab in a transgenic mouse model expressing human CD20 for clinical translation to image NHL. Mol Imaging Biol. 2012;14:608–16. [DOI] [PubMed]

77.

Lee CH, Lim I, Woo SK, Kim W, Kim KI, Lee KC, et al. Targeted alpha immunotherapy of CD20-positive B-cell lymphoma model: dosimetry estimate of ²²⁵Ac-DOTA-rituximab using ⁶⁴Cu-DOTA-rituximab. Ann Nucl Med. 2021;35:639–47. [DOI] [PubMed]

78.

Yoon JT, Longtine MS, Marquez-Nostra BV, Wahl RL. Evaluation of next-generation anti-CD20 antibodies labeled with ⁸⁹Zr in human lymphoma xenografts. J Nucl Med. 2018;59:1219–24. [DOI] [PubMed] [PMC]

79.

Lee I, Lim I, Lee KC, Kang HJ, Lim SM. ⁶⁴Cu-DOTA-rituximab PET/CT of B-cell non-Hodgkin lymphoma for imaging the CD20 expression. Clin Nucl Med. 2023;48:e82–3. [DOI] [PubMed]

80.

Jauw YW, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, et al. Performance of ⁸⁹Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large B cell lymphoma. PLoS One. 2017;12:e0169828. [DOI] [PubMed] [PMC]

81.

Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, et al. Tumour targeting and radiation dose of radioimmunotherapy with ⁹⁰Y-rituximab in CD20+ B-cell lymphoma as predicted by ⁸⁹Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging. 2015;42:1304–14. [DOI] [PubMed] [PMC]

82.

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031–42. [DOI] [PubMed]

83.

Zettlitz KA, Tavare R, Knowles SM, Steward KK, Timmerman JM, Wu AM. ImmunoPET of malignant and normal B cells with ⁸⁹Zr- and ¹²⁴I-labeled obinutuzumab antibody fragments reveals differential CD20 internalization in vivo. Clin Cancer Res. 2017;23:7242–52. [DOI] [PubMed] [PMC]

84.

Kang L, Li C, Rosenkrans ZT, Engle JW, Wang R, Jiang D, et al. Noninvasive evaluation of CD20 expression using ⁶⁴Cu-labeled F(ab’)₂ fragments of obinutuzumab in lymphoma. J Nucl Med. 2021;62:372–8. [DOI] [PubMed] [PMC]

85.

Poschenrieder A, Schottelius M, Osl T, Schwaiger M, Wester HJ. [⁶⁴Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model. EJNMMI Radiopharm Chem. 2017;2:2. [DOI] [PubMed] [PMC]

86.

Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5:618–30. [DOI] [PubMed] [PMC]